27405322|t|Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
27405322|a|Nivolumab has shown significant survival benefit and a favorable safety profile compared with dacarbazine chemotherapy among treatment-naïve patients with metastatic melanoma in the CheckMate 066 phase III study. Results from the health-related quality of life (HRQoL) analyses from CheckMate 066 are presented. HRQoL was evaluated at baseline and every 6 weeks while on treatment using the European Organisation for Research and Treatment of Care (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire (EQ-5D). Via a multi-step statistical plan, data were analyzed descriptively, cross-sectionally, and longitudinally, adjusting for baseline covariates, in patients having baseline plus ≥1 post-baseline assessment. Baseline-adjusted completion rates for all HRQoL questionnaires across treatment arms were 65% and 70% for dacarbazine and nivolumab, respectively, and remained similar throughout treatment. The mean baseline HRQoL scores were similar for patients treated with nivolumab and dacarbazine. Baseline HRQoL levels with nivolumab were maintained over time. This exploratory analysis showed a between-arm difference in favor of nivolumab on the EQ-5D utility index and clinically meaningful EQ-5D improvements from baseline at several time points for patients receiving nivolumab. Patients treated with nivolumab did not show increased symptom burden as assessed by the EORTC QLQ-C30. No HRQoL change was noted with dacarbazine patients up to week 43, although the high attrition rate after week 13 did not allow any meaningful analyses. Patients receiving nivolumab deteriorated significantly later than those receiving dacarbazine on several EORTC QLQ-C30 scales and the EQ-5D utility index. In addition to prolonged survival, these exploratory HRQoL results show that nivolumab maintains baseline HRQoL levels to provide long-term quality of survival benefit, compared with dacarbazine in patients with advanced melanoma.
27405322	0	6	Effect	T080	C1280500
27405322	10	19	nivolumab	T116,T121,T129	C3657270
27405322	23	53	health-related quality of life	T078	C4279947
27405322	57	65	patients	T101	C0030705
27405322	71	86	treatment-naïve	T201	C0919936
27405322	87	95	advanced	T080	C0205179
27405322	96	104	melanoma	T191	C0025202
27405322	106	113	results	T169	C1274040
27405322	123	152	phase III CheckMate 066 study	T062	C0282461
27405322	153	162	Nivolumab	T116,T121,T129	C3657270
27405322	185	201	survival benefit	T169	C0220921
27405322	218	232	safety profile	T058	C0150755
27405322	233	241	compared	T052	C1707455
27405322	247	258	dacarbazine	T109,T121	C0010927
27405322	259	271	chemotherapy	T061	C3665472
27405322	278	293	treatment-naïve	T201	C0919936
27405322	294	302	patients	T101	C0030705
27405322	308	327	metastatic melanoma	T191	C0278883
27405322	335	364	CheckMate 066 phase III study	T062	C0282461
27405322	366	373	Results	T169	C1274040
27405322	383	413	health-related quality of life	T078	C4279947
27405322	415	420	HRQoL	T078	C4279947
27405322	422	430	analyses	T062	C0936012
27405322	436	449	CheckMate 066	T062	C0008976
27405322	465	470	HRQoL	T078	C4279947
27405322	475	484	evaluated	T058	C0220825
27405322	488	496	baseline	T081	C1442488
27405322	509	514	weeks	T079	C0439230
27405322	524	533	treatment	T061	C0087111
27405322	544	653	European Organisation for Research and Treatment of Care (EORTC) Core Quality of Life Questionnaire (QLQ-C30)	T170	C3641780
27405322	662	699	EuroQoL Five Dimensions Questionnaire	T170	C2733251
27405322	701	706	EQ-5D	T170	C2733251
27405322	715	742	multi-step statistical plan	T170	C3889277
27405322	744	748	data	T078	C1511726
27405322	754	762	analyzed	T062	C0936012
27405322	763	776	descriptively	T170	C0678257
27405322	778	795	cross-sectionally	T062	C0010362
27405322	801	815	longitudinally	T062	C0023981
27405322	831	839	baseline	T081	C1442488
27405322	840	850	covariates	T080	C0439828
27405322	855	863	patients	T101	C0030705
27405322	871	879	baseline	T081	C1442488
27405322	888	901	post-baseline	T081	C1442488
27405322	902	912	assessment	T058	C0220825
27405322	914	948	Baseline-adjusted completion rates	T081	C1521828
27405322	957	962	HRQoL	T078	C4279947
27405322	963	977	questionnaires	T170	C0034394
27405322	985	999	treatment arms	T061	C1527374
27405322	1021	1032	dacarbazine	T109,T121	C0010927
27405322	1037	1046	nivolumab	T116,T121,T129	C3657270
27405322	1094	1103	treatment	T061	C0087111
27405322	1109	1122	mean baseline	T081	C1442488
27405322	1123	1128	HRQoL	T078	C4279947
27405322	1129	1135	scores	T081	C0449820
27405322	1153	1161	patients	T101	C0030705
27405322	1162	1169	treated	T061	C0087111
27405322	1175	1184	nivolumab	T116,T121,T129	C3657270
27405322	1189	1200	dacarbazine	T109,T121	C0010927
27405322	1202	1210	Baseline	T081	C1442488
27405322	1211	1216	HRQoL	T078	C4279947
27405322	1217	1223	levels	T080	C0441889
27405322	1229	1238	nivolumab	T116,T121,T129	C3657270
27405322	1255	1264	over time	T079	C0040223
27405322	1271	1291	exploratory analysis	T062	C0936012
27405322	1313	1323	difference	T081	C1705241
27405322	1336	1345	nivolumab	T116,T121,T129	C3657270
27405322	1353	1358	EQ-5D	T170	C2733251
27405322	1359	1372	utility index	T170	C0918012
27405322	1377	1387	clinically	T080	C0205210
27405322	1399	1404	EQ-5D	T170	C2733251
27405322	1405	1417	improvements	T077	C2986411
27405322	1423	1431	baseline	T081	C1442488
27405322	1443	1454	time points	T079	C2348792
27405322	1459	1467	patients	T101	C0030705
27405322	1478	1487	nivolumab	T116,T121,T129	C3657270
27405322	1489	1497	Patients	T101	C0030705
27405322	1498	1505	treated	T061	C0087111
27405322	1511	1520	nivolumab	T116,T121,T129	C3657270
27405322	1534	1543	increased	T081	C0205217
27405322	1544	1551	symptom	T184	C1457887
27405322	1552	1558	burden	T078	C2828008
27405322	1562	1570	assessed	T052	C1516048
27405322	1578	1591	EORTC QLQ-C30	T170	C3641780
27405322	1596	1601	HRQoL	T078	C4279947
27405322	1602	1608	change	T169	C0392747
27405322	1624	1635	dacarbazine	T109,T121	C0010927
27405322	1636	1644	patients	T101	C0030705
27405322	1651	1655	week	T079	C0439230
27405322	1678	1692	attrition rate	UnknownType	C0814623
27405322	1699	1703	week	T079	C0439230
27405322	1736	1744	analyses	T062	C0936012
27405322	1746	1754	Patients	T101	C0030705
27405322	1765	1774	nivolumab	T116,T121,T129	C3657270
27405322	1829	1840	dacarbazine	T109,T121	C0010927
27405322	1852	1865	EORTC QLQ-C30	T170	C3641780
27405322	1866	1872	scales	T077	C0549193
27405322	1881	1886	EQ-5D	T170	C2733251
27405322	1887	1900	utility index	T170	C0918012
27405322	1917	1935	prolonged survival	T169	C0220921
27405322	1955	1960	HRQoL	T078	C4279947
27405322	1961	1968	results	T169	C1274040
27405322	1979	1988	nivolumab	T116,T121,T129	C3657270
27405322	1999	2007	baseline	T081	C1442488
27405322	2008	2013	HRQoL	T078	C4279947
27405322	2014	2020	levels	T080	C0441889
27405322	2032	2041	long-term	T079	C0443252
27405322	2042	2069	quality of survival benefit	T033	C0808134
27405322	2071	2079	compared	T052	C1707455
27405322	2085	2096	dacarbazine	T109,T121	C0010927
27405322	2100	2108	patients	T101	C0030705
27405322	2114	2122	advanced	T080	C0205179
27405322	2123	2131	melanoma	T191	C0025202